Huiling Lü
Impact in
- Microbiology top 2%
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
-
- Metabolism, Diabetes, and Cancer 2
- Receptor Mechanisms and Signaling 2
- Epidemiology 15
- Adipokines, Inflammation, and Metabolic Diseases 12
- Co-authors
- Alexander Luft (1 shared paper)Martin Sebastian (1 shared paper)Martin Reck (1 shared paper)Jean-Marie Cuillerot (1 shared paper)Thomas J. Lynch (1 shared paper)Raju Titus Chacko (1 shared paper)Fabrice Barlési (1 shared paper)Igor Bondarenko (1 shared paper)
- Journals
- Journal of Cellular Biochemistry (3 papers)PLoS ONE (3 papers)Medicine (2 papers)Oncology Reports (2 papers)Signal Transduction and Targeted Therapy (1 paper)
- Partner nations
- ChinaCanadaUnited States
In The Last Decade
Huiling Lü
66 papers receiving 2.0k citations
Huiling Lü's Hit Papers
Peers
Comparison fields: 5 of 121
- Microbiology 35
- Oncology 532
- Immunology 369
- Endocrine and Autonomic Systems 111
- Epidemiology 438
Countries citing papers authored by Huiling Lü
This map shows the geographic impact of Huiling Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huiling Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huiling Lü more than expected).
Fields of papers citing papers by Huiling Lü
This network shows the impact of papers produced by Huiling Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huiling Lü. The network helps show where Huiling Lü may publish in the future.
Co-authors
The 25 scholars most cited alongside Huiling Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Hit paper breakdown → | 2012 | 513 |
| 2 | 2005 | 80 | |
| 3 | 2018 | 80 | |
| 4 | 2019 | 79 | |
| 5 | 2006 | 68 | |
| 6 | 2007 | 66 | |
| 7 | 2010 | 64 | |
| 8 | 2006 | 59 | |
| 9 | 2022 | 57 | |
| 10 | 2005 | 51 | |
| 11 | 2007 | 46 | |
| 12 | 2005 | 46 | |
| 13 | 2005 | 45 | |
| 14 | 2021 | 44 | |
| 15 | 2012 | 40 | |
| 16 | 2019 | 38 | |
| 17 | 2012 | 38 | |
| 18 | 2018 | 33 | |
| 19 | 2018 | 33 | |
| 20 | 2017 | 30 |
About Huiling Lü
Huiling Lü is a scholar working on Molecular Biology, Epidemiology, Physiology, Pharmacology and Oncology, having authored 67 papers that have together received 2.0k indexed citations. Recurring topics across this work include Adipokines, Inflammation, and Metabolic Diseases (12 papers), Adipose Tissue and Metabolism (8 papers), Apelin-related biomedical research (4 papers), Regulation of Appetite and Obesity (3 papers), Neuropeptides and Animal Physiology (3 papers), Metabolism, Diabetes, and Cancer (2 papers), Receptor Mechanisms and Signaling (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Microbiology (35 citations), Oncology (532 citations), Immunology (369 citations), Endocrine and Autonomic Systems (111 citations) and Epidemiology (438 citations). Huiling Lü has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Alexander Luft, Martin Sebastian, Martin Reck, Jean-Marie Cuillerot, Thomas J. Lynch, Raju Titus Chacko, Fabrice Barlési, Igor Bondarenko, Piotr Serwatowski and Katherine Cianflone. Their work appears in journals such as Journal of Cellular Biochemistry, PLoS ONE, Medicine, Oncology Reports and Signal Transduction and Targeted Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.